Skip to main content
SciBX: Science-Business eXchange
As published Thursday, July 17, 2014

  • Cover Story: Fixing mitophagy in Parkinson's disease

    By Kai-Jye Lou, Senior Writer

    Fixing mitophagy in Parkinson's disease

    Genentech Inc. has identified ubiquitin specific peptidase 30 as a potentially disease-modifying target involved in the clearance of damaged mitochondria in Parkinson's disease.1 The Roche unit now needs to determine whether the deubiquitinase is indeed druggable.

    Full Article
  • Partnering in pediatrics

    Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.

  • New route for old cancer agents

    Researchers at the University of Wisconsin-Madison and Cellectar Biosciences have improved the safety of broad-spectrum cytotoxic drugs by engineering molecules that specifically target malignant cells. The key was exploiting differences in lipid architecture between the two types of cells.

  • Hedgehog joins the resistance

    Hedgehog-mediated degradation of chemotherapeutics is a key resistance mechanism in AML, according to findings from Canadian researchers. Their next step is clinical testing of a chemotherapy-hedgehog antagonist combination.


  • This Week in Therapeutics

    Stabilizing PLA2G5 or inhibiting PLA2G2E to treat obesity; using NOGO-A inhibitors and then physical therapy to improve motor recovery after stroke; antagonizing ABL1 to block neovascularization in retinopathy; and more...

  • more therapeutics news
  • This Week in Techniques

    Predicting epidemic variants of mosquito-borne RNA viruses using an in vivo infection system; inducing broadly neutralizing antibodies with an influenza A virus hemagglutinin stem fragment; monitoring miR-1202 expression to predict antidepressant treatment response; and more...

  • more techniques news
Subscribe Now
Free Trial